Americas (WHO region) vs Chad: Hepatitis B surface antigen (HBsAg) prevalence (%)
Americas (WHO region)
0.0%
in 2024
Chad
2.2%
in 2024
Americas (WHO region) rank
12th
Chad rank
11th
Hepatitis B surface antigen (HBsAg) prevalence (%) over time
- Americas (WHO region)
- Chad
How they compare
Chad currently reports 2.2% against 0.0% in Americas (WHO region), a difference of 2.2%.
Across all 10 years both countries report, Chad has been ahead every year.
Americas (WHO region) ranks 12th and Chad ranks 11th of 13 groups.
Chad has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Americas (WHO region) | Chad | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.0% | 4.1% | 4.1% | Chad |
| 2020s | 0.0% | 3.0% | 3.0% | Chad |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Americas (WHO region) or Chad?
- Chad, at 2.2% against 0.0% in Americas (WHO region) as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Americas (WHO region) and Chad?
- 2.2%, with Chad ahead.
- How many years of comparable data are there for Americas (WHO region) and Chad?
- 10 years are reported by both, from 2015 to 2024.
- How do Americas (WHO region) and Chad rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Americas (WHO region) ranks 12th and Chad ranks 11th of 13 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.